Johnson & Johnson to acquire Firefly Bio for $1 billion to add Firelink DAC platform
- Johnson & Johnson will acquire Firefly Bio for $1 billion in cash.
- The transaction is expected to close later this year, subject to regulatory approvals and customary closing conditions.
- Firefly’s Firelink™ degrader antibody conjugate (DAC) platform delivers a selective protein degrader to tumour cells and is directed at KRAS-driven solid tumours.
- Johnson & Johnson says the platform will supply preclinical candidates and bolster its oncology pipeline targeting hard-to-treat solid tumours.
Deal terms
Johnson & Johnson has entered a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. The closing is expected later this year, subject to applicable regulatory approvals and other customary closing conditions; the accounting treatment will be communicated on or before close.
Technology and scientific rationale
Firefly Bio’s proprietary Firelink™ degrader antibody conjugate (DAC) platform is designed to deliver a highly selective protein degrader to tumour cells while avoiding healthy cells. The platform is being advanced for KRAS-driven tumours, a class of solid cancers the companies describe as prevalent and hard to treat.
Strategic context and company view
The deal is presented as a complement to Johnson & Johnson’s existing antibody engineering capabilities and oncology pipeline. Company leadership highlighted KRAS as a historically undruggable target and stated the Firelink™ platform could overcome current treatment limitations and diversify the pipeline with preclinical candidates for multiple solid tumour types.
Source: J&J
